anitocabtagene autoleucel

AXP000022.1 · CAR-T cell therapy

Platform
autologous CAR-T
Targets
TNFRSF17
Originator
Arcellx
Sponsor
Kite Pharma (Gilead Sciences)

Names

NameTypeSource
anitocabtagene autoleucelpreferred name, INNcurator, ncit
anito-celsynonymncit
CART-ddBCMAformer codencit
ddBCMA ambiguousformer namepress

Virus

Role
Ex vivo gene transfer
Family
Retroviridae
Virus
lentivirus
Replication
non replicating
Modifications
lentiviral vector carrying a CAR whose binding domain is a synthetic 73-amino-acid D-domain against BCMA, fused to a CD8 hinge and transmembrane region with 4-1BB and CD3 zeta intracellular signalling domains
Transgenes
anti-BCMA chimeric antigen receptor (D-domain binder)
Route
ex vivo, intravenous
Carrier
autologous T cells
Source
evidence

Cross-references

NCI Thesaurus
C199003
FDA UNII
WQD5K35YZT

Approvals

No regulatory approval recorded.

Clinical trials (8)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07903506To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 32027-022039-03750Newly Diagnosed Multiple Myeloma
NCT07887672A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 32027-012042-02600Newly Diagnosed Multiple Myeloma
NCT07045909Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)RecruitingPhase 22025-06-302028-03-3130Anitocabtagene Autoleucel; De Novo Multiple Myeloma
NCT06626919Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related DiseasesRecruitingPhase 12025-04-302028-1030Autoimmune; Autoimmune Diseases; Autoimmune Diseases of the Nervous System; Muscle Weakness; Muscular Diseases; Myasthenia Gravis; Neuromuscular Manifestations
NCT06413498A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple MyelomaActive not recruitingPhase 32024-08-232028-07452Multiple Myeloma
NCT05396885Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)Active not recruitingPhase 22022-07-152026-12136Multiple Myeloma
NCT05041309Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite StudiesEnrolling by invitation2021-12-152040-121500Autoimmune Diseases; Solid and Hematological Malignancies
NCT04155749Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple MyelomaActive not recruitingPhase 12019-12-232024-10-0340Relapsed and Refractory Multiple Myeloma

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 42036693Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.Journal of hematology & oncology2026cited by trial NCT05041309
PMID 42777241Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma.The New England journal of medicine2026cited by trial NCT04155749
PMID 35468618Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.Blood advances2023cited by trial NCT04155749
PMID 35737298Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain.Molecular cancer therapeutics2022cited by trial NCT04155749

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 414286222025 Update of Cellular Immunotherapy for Plasma Cell Disorders.Turkish journal of haematology : official journal of Turkish Society of Haematology2026name in abstract: anito-cel
PMID 42724501Long-term safety and efficacy of BCMA-directed CAR T-cell therapies in multiple myeloma: comparative insights from Cilta-cel, Ide-cel, Anito-cel, and FCARH143.Translational cancer research2026name in title: anito-cel
PMID 42777246Anito-cel for Multiple Myeloma.The New England journal of medicine2026name in title: anito-cel

Notes

Anti-BCMA CAR with synthetic D-domain binder. Gilead acquired Arcellx in 2026; BLA under FDA review (PDUFA 2026-12-23).

How to cite

anitocabtagene autoleucel (AXP000022.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000022.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.